Literature DB >> 34183755

KCNN4-mediated Ca2+/MET/AKT axis is promising for targeted therapy of pancreatic ductal adenocarcinoma.

Xiao Mo1,2, Cheng-Fei Zhang1,2, Ping Xu2, Min Ding2, Zhi-Jie Ma2, Qi Sun2, Yu Liu1, Hong-Kai Bi1,2, Xin Guo1,2, Alaa Abdelatty2, Chao Hu2, Hao-Jun Xu1,2, Guo-Ren Zhou3, Yu-Liang Jia4, Hong-Ping Xia5,6,7.   

Abstract

As a member of the potassium calcium-activated channel subfamily, increasing evidence suggests that KCNN4 was associated with malignancies. However, the roles and regulatory mechanisms of KCNN4 in PDAC have been little explored. In this work, we demonstrated that the level of KCNN4 in PDAC was abnormally elevated, and the overexpression of KCNN4 was induced by transcription factor AP-1. KCNN4 was closely correlated with unfavorable clinicopathologic characteristics and poor survival. Functionally, we found that overexpression of KCNN4 promoted PDAC cell proliferation, migration and invasion. Conversely, the knockdown of KCNN4 attenuated the growth and motility of PDAC cells. In addition to these, knockdown of KCNN4 promoted PDAC cell apoptosis and led to cell cycle arrest in the S phase. In mechanistic investigations, RNA-sequence revealed that the MET-mediated AKT axis was essential for KCNN4, encouraging PDAC cell proliferation and migration. Collectively, these findings reveal a function of KCNN4 in PDAC and suggest it's an attractive therapeutic target and tumor marker. Our studies underscore a better understanding of the biological mechanism of KCNN4 in PDAC and suggest novel strategies for cancer therapy.
© 2021. The Author(s), under exclusive licence to CPS and SIMM.

Entities:  

Keywords:  AKT; KCNN4; MET; pancreatic ductal adenocarcinoma; proliferation

Mesh:

Substances:

Year:  2021        PMID: 34183755      PMCID: PMC8888650          DOI: 10.1038/s41401-021-00688-3

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  33 in total

Review 1.  Targeting MET in cancer: rationale and progress.

Authors:  Ermanno Gherardi; Walter Birchmeier; Carmen Birchmeier; George Vande Woude
Journal:  Nat Rev Cancer       Date:  2012-01-24       Impact factor: 60.716

2.  The potassium channel KCa3.1 promotes cell proliferation by activating SKP2 and metastasis through the EMT pathway in hepatocellular carcinoma.

Authors:  Yehui Du; Wenfeng Song; Jian Chen; Hao Chen; Zefeng Xuan; Long Zhao; Jun Chen; Cheng Jin; Mengqiao Zhou; Biguang Tuo; Yongchao Zhao; Shusen Zheng; Penghong Song
Journal:  Int J Cancer       Date:  2019-02-08       Impact factor: 7.396

3.  IL-17 stimulates the expression of CCL2 in cardiac myocytes via Act1/TRAF6/p38MAPK-dependent AP-1 activation.

Authors:  Shiyou Du; Zhuolun Li; Xin Xie; Congfeng Xu; Xinhe Shen; Nan Wang; Yan Shen
Journal:  Scand J Immunol       Date:  2019-10-20       Impact factor: 3.487

4.  Dysbindin promotes progression of pancreatic ductal adenocarcinoma via direct activation of PI3K.

Authors:  Cheng Fang; Xin Guo; Xing Lv; Ruozhe Yin; Xiaohui Lv; Fengsong Wang; Jun Zhao; Quan Bai; Xuebiao Yao; Yong Chen
Journal:  J Mol Cell Biol       Date:  2017-12-01       Impact factor: 6.216

5.  KCa3.1 (IK) modulates pancreatic cancer cell migration, invasion and proliferation: anomalous effects on TRAM-34.

Authors:  B Bonito; D R P Sauter; A Schwab; M B A Djamgoz; I Novak
Journal:  Pflugers Arch       Date:  2016-10-17       Impact factor: 3.657

6.  Kcnn4 is a regulator of macrophage multinucleation in bone homeostasis and inflammatory disease.

Authors:  Heeseog Kang; Audrey Kerloc'h; Maxime Rotival; Xiaoqing Xu; Qing Zhang; Zelpha D'Souza; Michael Kim; Jodi Carlson Scholz; Jeong-Hun Ko; Prashant K Srivastava; Jonathan R Genzen; Weiguo Cui; Timothy J Aitman; Laurence Game; James E Melvin; Adedayo Hanidu; Janice Dimock; Jie Zheng; Donald Souza; Aruna K Behera; Gerald Nabozny; H Terence Cook; J H Duncan Bassett; Graham R Williams; Jun Li; Agnès Vignery; Enrico Petretto; Jacques Behmoaras
Journal:  Cell Rep       Date:  2014-08-14       Impact factor: 9.423

7.  ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors.

Authors:  Freddy E Escorcia; Jacob L Houghton; Dalya Abdel-Atti; Patricia R Pereira; Andrew Cho; Nicholas T Gutsche; Kwamena E Baidoo; Jason S Lewis
Journal:  Theranostics       Date:  2020-01-01       Impact factor: 11.556

8.  Endoplasmic Reticulum stress-dependent expression of ERO1L promotes aerobic glycolysis in Pancreatic Cancer.

Authors:  Junfeng Zhang; Jianyu Yang; Chaoyi Lin; Wei Liu; Yanmiao Huo; Minwei Yang; Shu-Heng Jiang; Yongwei Sun; Rong Hua
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

9.  Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.

Authors:  Lingdi Yin; Ning Pu; Christopher Wolfgang; Jun Yu; Elizabeth Thompson; Yi Miao
Journal:  Clin Cancer Res       Date:  2020-10-20       Impact factor: 12.531

10.  Exome-wide analysis identifies three low-frequency missense variants associated with pancreatic cancer risk in Chinese populations.

Authors:  Jiang Chang; Jianbo Tian; Ying Zhu; Rong Zhong; Kan Zhai; Jiaoyuan Li; Juntao Ke; QiangQiang Han; Jiao Lou; Wei Chen; Beibei Zhu; Na Shen; Yi Zhang; Yajie Gong; Yang Yang; Danyi Zou; Xiating Peng; Zhi Zhang; Xuemei Zhang; Kun Huang; Ming Yang; Li Wang; Chen Wu; Dongxin Lin; Xiaoping Miao
Journal:  Nat Commun       Date:  2018-09-11       Impact factor: 14.919

View more
  1 in total

1.  KCNN4 is a Potential Biomarker for Predicting Cancer Prognosis and an Essential Molecule that Remodels Various Components in the Tumor Microenvironment: A Pan-Cancer Study.

Authors:  Shaohua Chen; Xiaotao Su; Zengnan Mo
Journal:  Front Mol Biosci       Date:  2022-06-03
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.